What Are Wall Street Analysts' Target Price for Incyte Stock?

Barchart
Open on Barchart
What Are Wall Street Analysts' Target Price for Incyte Stock?

Headquartered in Wilmington, Delaware, Incyte Corporation (INCY) is a global biopharmaceutical company that discovers, develops, and commercializes treatments for patients with unmet medical needs. With a market capitalization of $24.3 billion, the company focuses on hematology, oncology, inflammation, and autoimmune diseases, supported by research and clinical development programs across multiple disease areas.

Shares of this multinational biopharmaceutical company have outpaced the broader market over the past year. INCY has gained 13.4% over this period, while the broader S&P 500 Index ($SPX) has climbed nearly 10.7%. Likewise, the stock has significantly outperformed the index in 2026, rising 19.3% year-to-date, compared with the S&P 500’s 7% gain over the same period.

More Top Stocks Daily: Go behind Wall Street’s hottest headlines with Barchart’s Active Investor newsletter.

 

Compared with the iShares Biotechnology ETF (IBB), however, INCY has underperformed over the past year. The ETF has gained 23.4% over this period and 21.7% year-to-date.

www.barchart.com

On Oct. 29, 2026, Incyte reported Q3 results, with total revenue increasing 14% year over year to $1.56 billion. Total net product revenue rose 14.5% to $1.32 billion, led by 36% growth in Opzelura sales to $255 million and a 38% increase in Hematology and Oncology sales to $235 million. Jakafi sales grew 4% to $827 million. However, Incyte reported a non-GAAP diluted loss of $3.60 per share, compared with earnings of $2.26 per share a year earlier, primarily reflecting a $1.23 billion acquired in-process research and development charge related to its acquisition of Vega Therapeutics. Following the results, INCY shares declined marginally before rebounding 3.1% in the next trading session.

For fiscal 2026, Incyte raised its total net product revenue guidance to a range of $5.21 billion to $5.30 billion, up from its previous outlook of $5.13 billion to $5.26 billion. The company also increased its Opzelura sales forecast to $1.10 billion to $1.12 billion and its Hematology and Oncology sales outlook to $890 million to $910 million, while maintaining guidance for its other product categories.

On Nov. 16, 2026, Incyte announced that the European Commission had approved Povofortay (povorcitinib) for eligible adults with moderate to severe hidradenitis suppurativa, marking an important commercial milestone. Supported by positive Phase 3 STOP-HS1 and STOP-HS2 results, the approval expands Incyte’s inflammation portfolio and provides a potential new revenue source. Meanwhile, the U.S. Food and Drug Administration is reviewing the application, with approval and launch anticipated in the first quarter of 2027.

For the fiscal year ending in December 2026, analysts expect INCY’s diluted EPS to rise 59% year-over-year to $2.29. INCY has beaten consensus EPS estimates in three of the past four quarters while missing expectations in one.

Based on the 28 analysts covering INCY stock, the consensus rating is a “Moderate Buy.” The rating is based on 13 “Strong Buys” and 15 “Holds.”

www.barchart.com

The analyst configuration is more bullish now compared with a month ago, when INCY had 12 “Strong Buy” recommendations.

On Nov. 17, 2026, Piper Sandler analyst Allison Bratzel maintained a “Buy” rating on Incyte with a price target of $130.

Based on analysts’ estimates, INCY’s mean price target of $133.64 implies a 13.4% upside, while the Street-high target of $157 represents a 33.3% premium.


On the date of publication, Abhishek Bhuyan did not directly have a position in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here.

 

More news from Barchart

Berkshire Might Give Up on This High-Yielding Dividend Stock. You Maybe Should Too. $1.6 Billion Loss: Billionaire Bill Ackman Says He Was ‘A Little Bit Surprised’ by Berkshire’s $10 Billion Alphabet Bet, ‘They Got It at a 6% Discount, But So What?’ Dear Sandisk Stock Fans, Mark Your Calendars for November 20 The Downside Risk in Stocks Is Still High, According to My 'Short List'